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Abstract 
Background: Ventilator-associated pneumonia (VAP) is associated with significant morbidity, 
mortality and healthcare costs. Most of the cost data that are available relate to general intensive care 
patients in privately remunerated institutions. This study assessed the cost of managing VAP in a 
cardiac intensive care unit (CICU) in the National Health Service (NHS) in the United Kingdom. 
Methods: Propensity-matched study of prospectively collected data from the cardiac surgical 
database between April 2011 and December 2014 in all patients undergoing cardiac surgery 
(n=3416). Patients who were diagnosed as developing VAP, as per the surveillance definition for VAP 
(n=338), were propensity score matched with those who did not (n=338). Costs of treating post-op 
cardiac surgery patients in intensive care and cost difference if VAP occurred based on Healthcare 
Resource Group (HRG) categories was assessed. Secondary outcomes included differences in 
morbidity, mortality and CICU and in-hospital length of stay.  
Results: There were no significant differences in the pre-operative characteristics or procedures 
between the groups. VAP developed in 10% of post-cardiac surgery patients. Post-operatively, the 
VAP group required longer ventilation (p<0.01), more respiratory support, longer CICU (8 v/s 3, 
p<0.001), and in-hospital stay (16 v/s 9) days. The overall cost for post-operative recovery after 
cardiac surgery for VAP patients was £15,124 compared to £6,295 for non-VAP (p<0.01). The 
additional cost of treating patients with VAP was £8,829. 
Conclusion: VAP was associated with significant morbidity to the patients, generating significant 
costs. This cost was nearer to the lower end for the cost for general ICU patients in privately 
reimbursed systems.  
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Introduction 
Ventilator-Associated Pneumonia (VAP) is associated with significant patient morbidity and mortality 
(1-3). It has also been suggested that there are significant cost implications when treating patients 
with VAP (4–6). VAP is recognised as one of the healthcare associated infections (HAI) along with 
surgical site infection (SSI), central line associated blood stream infection (CLABSI), catheter-
associated urinary tract infection (CAUTI) and clostridium difficile infection (CDI) [7] which bears 
heavily on the health system and are very preventable.  
A number of studies have attempted to estimate the economic burden of VAP and have reported 
costs ranging from $10,000 to $40,000 per patient treated (7–10).  However, most of these studies 
were based in general intensive care (ICU) patients within healthcare systems such as in the USA 
where the hospitals were reimbursed by a private health insurer. VAP can develop within any group of 
patients who are ventilated for a period of time even when this period is less than 24 hours, such as in 
patients undergoing cardiac surgery (11). As the management of VAP is the same whether the patient 
is a general ICU patient or a cardiac surgical patient on CICU, similar cost implications may apply.  
In the UK, the healthcare system is provided mostly by the government funded National Health 
Service (NHS) and hospitals are remunerated via a payment by results (PbR) system using nationally 
agreed tariffs. The latter is calculated using clinical codes grouped together by the Healthcare 
Resource Group (HRG) (12). Each HRG is assigned a cost, which reflects the required expenditure 
for providing a specified package of care, and there are specific HRG costs for intensive care stay 
depending on the number of body organs being supported. When patients develop VAP, these costs 
can escalate to a significant sum (7–10). This increase in costs reflects the additional need for 
manpower, equipment use and drug treatments. The HRG costs based on specific HRG codes are 
listed in Table 1. 
The aim of this study is to assess the costs to the NHS when treating VAP in a cardiac surgical 
population using the HRG codes given to healthcare providers in England.  
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Material and methods 
All patients undergoing cardiac surgery at our centre during the period of April 2011 to December 
2014 were initially selected (n=3416).  Patients who were diagnosed to have developed definite VAP 
were included in the VAP group (n=342). VAP was diagnosed using the CDC definition (13) as well as 
the HELICS clinical criteria (14). Two definitions were used in conjunction with each other, as the VAP 
criteria are regularly updated and these two definitions were active during the study period. The 
diagnosis of VAP included patients who demonstrated new and/or progressive pulmonary infiltrates 
on a chest radiograph, along with two or more of the following: fever (>38.5
0
C) or hypothermia 
(<36
0
C), leukocytosis (>12 x10
9
/L), purulent tracheobronchial secretions, or a reduction in PaO2/FiO2 
(partial pressure of arterial oxygen/ fraction of inspired oxygen) of 15% or more in the previous 48 
hours. Patients also had positive bacteriologic cultures (14). As per the CDC definition patients were 
diagnosed as having VAP irrespective of the duration of intubation (13). Based on these definitions, 
only patients who were classed as having definite VAP were included in the study.
 
Moreover, only 
patients who developed a pneumonia as their first main complication were included. Thus, patients 
who developed another complication e.g. low renal output and then developed a pneumonia, were 
excluded. Complete data needed for patient matching and data analysis were available for 338 VAP 
patients (99%) (Study group). Patients in the VAP group were then matched according to propensity 
score to create a non-VAP patient group (control, n=338). Prospectively collected data for the patients 
were then retrieved from our databases (Dendrite Cardiac surgery and Medtrack Intensive Care). This 
study was agreed by the Hospital’s Research and Development Department. Ethical approval for this 
study (Ethical Committee REC reference number: 15/WS/0142).  
Our antibiotic prophylaxis includes intravenous gentamicin and flucloxacillin prior to skin incision 
followed by flucloxacillin 6-hourly for 24 hours post-op. Patients allergic to penicillin are given 
teicoplanin (single dose).  
Patients are extubated when they fulfil the following criteria: 
 They are adequately warm 
 They do not require high ventilatory / FiO2 support 
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 They are haemodynamically stable and are unlikely to need to return to the operating room 
 They are awake and co-operative enough to maintain their airway and obey simple commands 
Our VAP prevention bundles include appropriate hand hygiene, changing of ventilator circuits when 
soiled, or at 7 days whichever was sooner, semi recumbent positioning whenever clinically possible 
and Chlorhexidine 2% oral mouth wash 6 hourly whilst intubated. All patients routinely received 
gastric stress ulcer prophylaxis with Ranitidine 50mg I.V. 8 hourly. 
A logistic regression model was used to generate a propensity score for each patient. This can be 
considered as the probability of contracting a chest infection and is based on patient and procedure 
characteristics. The following variables were considered for the propensity score model: age, sex, 
ethnicity, BMI, smoking history, diabetes management, operation year, CABG, other cardiac 
procedure, major aortic procedure, valve surgery, urgency, ejection fraction, extra cardiac 
arteriopathy, history of pulmonary disease, renal function, bypass time, pre-operative haemoglobin, 
creatinine and Euroscore. Cardiopulmonary bypass time, pre-operative haemoglobin, creatinine and 
Euroscore were log transformed prior to entry into the model. For each patient in the VAP group, an 
individual was selected in the non-VAP group by matching on the log of the estimated propensity 
score, using a nearest neighbour matching algorithm with callipers (an interval) of maximum width of 
0.2 standard deviations (SDs). The distribution of all model factors was compared in the two groups to 
assess the success of the propensity score model. In line with recommendations, the balance in the 
covariates across the two groups was considered achieved if the standardised differences were less 
than 10% (15). The first model for the propensity score containing all the above variables was 
considered a success as all standardised differences were less than 10%. Hence, no further models 
were considered. 
In order to estimate the cost for treating VAP, resource use associated with each patient was 
retrieved from the hospital’s database. This contained two pieces of information: (a) the various HRGs 
incurred by each patient and (b) the number of days spent at each HRG. Unit costs were taken from 
the 2013-2014 Reference Costs (National Schedule of Reference Costs, 2014) and total patient cost 
was obtained by multiplying resource use by the unit costs. Finally, the cost of VAP was calculated as 
the difference in the cost between the VAP and non-VAP cohorts.  
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As the cost data were right skewed, they were analysed using the non-parametric bootstrap statistical 
technique (16,17). The 95% bias-corrected accelerated (BCa) confidence intervals around the means 
were calculated by running 10,000 sampling replications. All bootstrap computations were performed 
in R (18). 
Categorical data are expressed as percentage and differences between the two groups assessed 
using the chi square (χ
2
) test of independence. Continuous variables are expressed as mean (SD) or 
median (range) for Gaussian and skewed distributed data respectively. Likewise, group comparisons 
were carried out using the t-test or non-parametric (Mann-Whitney U) test accordingly. Tests were 
considered significant at p≤ 0.05. Statistical analyses were carried out in SPSS version 20 (IBM, 
SPSS package) and STATA 12 (StataCorp).  
Results 
Ten percent (342/3416) of patients undergoing cardiac surgery during the study period developed 
VAP. There were no significant differences between the two groups in terms of patients' pre-op 
characteristics (Table 2). The types of surgery and the priority for the need for surgery were also not 
significantly different (Table 2). The median intubation times were 16 (8,1680) for the VAP and 16 
(8,1008) hours for the non-VAP groups (p <0.01). Only 3% (105/3416) of patients required ventilation 
for more than 48 hours. Post-operatively patients in the VAP group required longer ventilation period 
(p< 0.01) and additional respiratory support (p< 0.01) such as facial CPAP (continuous positive airway 
pressure), re-intubation and tracheostomy (Table 3). Positive bacteriological cultures were obtained in 
VAP patients from either BAL or sputum samples. The various pathogens identified included: Gram-
negative bacteria in 43% (Haemophilus Influenzae being most common – 34%, Klebsiella 
Pneumoniae -13%, Coliform species -10%, Pseudomonas Aeruginosa - 10%, Escherichia coli - 10% 
and others - 23%), Gram-positive bacteria in 7% (Staphylococcus aureus - 69%, streptococcus 
species - 31%) and a fungal component (mostly Candida albicans) in 21%. Of note, given that these 
samples were obtained from a combination of BALs and sputum culture, 51% had a mixed growth 
pattern on microscopy.  10.4% (35 patients) in the VAP group required a tracheostomy as part of their 
ventilator wean.  
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The median ICU stay was significantly different between VAP and non-VAP patients, being 7.8 (0,74) 
and 2.9 days (0,46) respectively (p< 0.01) as was the in-hospital stay 16.2 (4,137) and 8.6 days (4, 
64) respectively (p <0.01). However, there were no significant differences in mortality (4.7% v/s 3.3%, 
p=0.2). 
The cost of treating VAP patients was significantly higher than for non-VAP patients (Table 4). This 
amounted to an additional cost of £8,829 (BCa 95% CI = 6,937-11,189) per patient when VAP 
occurred.  
Discussion 
This is the first UK-based study (where HealthCare delivery is essentially free)  assessing the cost of 
treating VAP in cardiac surgical patients. It confirmed the significant morbidity, prolonged ICU and in-
hospital stays which have been previously described (3,11) and provides a realistic estimate of the 
cost for treating VAP in a non-profit making medical institution.  
The duration of mechanical ventilation was not included in the propensity score matching (PSM) 
model because it is well recognised that VAP patients usually require longer ventilation as compared 
to non-VAP patients. This current study was set up to assess the cost of VAP rather than its causes 
and if duration of mechanical ventilation was used in the PSM model, then there would have been a 
large number of patients in the VAP group who would not be matched and would have been excluded 
from the study group and would not have provided a true clinical progress picture. Thus, it would have 
defeated the purpose of the cost calculations, as it is the longer duration of mechanical ventilation 
along with its ensuing complications such as sepsis and renal failure, which generates the high cost of 
treating patients with VAP.  
The costs were calculated as the difference between the VAP and the non-VAP cohorts. This 
comparative method of calculating the cost of VAP has also been used by most other authors who 
have reported a cost of VAP, and certainly by authors who conducted primary data analysis (as 
opposed to systematic reviews) (7-9). In accordance with best practice, the confidence intervals of the 
cost of VAP were computed using bootstrapping (16,19). Being a Monte Carlo-based, non-parametric 
technique, the bootstrap does not make any assumption about the underlying distribution of the data 
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and it has therefore the ability to generate more realistic estimates of the uncertainty around the mean 
than would be the case with standard parametric statistical procedures (16). 
It is widely acknowledged that VAP leads to morbidity and use of resources which could have been 
deployed elsewhere. Despite this, there is a lack of accurate estimates of the cost of VAP in the UK. 
In this study a combination of the CDC definition (13) and HELICS clinical criteria were used (14). It is 
recognised that other definitions are in use e.g. CPIS (20) and the varied definitions used in other 
studies might account for the differences in the VAP rates reported, the differing bacteriological 
agents and the mortality associated with VAP (20,21). Over the last decade, the VAP definitions have 
been ever-changing and newer concepts such as Ventilator associated Complications (VAC) are 
becoming more popular (22). During the period of this study the HELICS definitions used, were the 
most topical. However, from a clinical perspective, irrespective of the definition, patients experience 
significant morbidity when a chest infection ensues after a period of intubation. The infection can 
develop even after a few hours of intubation as reported by Gopal et al, when VAP was seen in 
patients undergoing cardiac surgery after a median intubation time of 15 hours (11), further supporting 
the notion that the endotracheal tube is a recognised modifiable risk factor, that can reduce the risk of 
VAP (23).  
With £8,829, the cost of VAP calculated in this study is lower than that generally reported in the 
literature. In a systematic review, Safdar et al (10) present the pooled cost estimate from their 
literature survey. They report a mean cost between $10,019 - $13,647 (in 2005 US Dollars), which did 
not include physician charges and is therefore likely to be conservative. They also report a mean 
increase in ICU LOS of 6.1 days. Patients had to have been on ventilation for at least 48 hours. 
Restrepo et al (9), in a retrospective analysis of the NASCENT clinical trial, report a median cost of 
approximately $20,000 (in 2010 US Dollars), which is also an underestimate of the average cost, 
given that costs are generally right skewed with the consequence that the mean is always greater 
than the median. The median incremental LOS was 10.5 days for ICU stay and 12.5 for total hospital 
stay. VAP diagnostic was microbiologically confirmed and patients had to be intubated for at least 24 
hours. Kollef et al (3), in a large observational hospital database study published in 2012, present a 
mean cost of VAP of $39,828. The reported increase in mean LOS was 8.9 days in the ICU and 13.1 
days for total hospitalisation. VAP was identified via the ICD-9 code 997-31 and only patients with at 
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least 48 hours of mechanical ventilation were included in the analysis. Finally, based on a systematic 
review, Zimlichman et al (7) report a mean cost of $40,144 (in 2012 US Dollars). The additional mean 
ICU LOS was 8.4 days and it was 13.1 days for hospitalisation overall. The diagnosis of VAP followed 
the CDC definition.  
In our study, the mean additional LOS due to VAP was 4.8 days for ICU stay and 7.6 for overall 
hospitalisation. These incremental LOS values are smaller than those of the literature cited above and 
this may partly explain the lower cost of VAP found in this study. However, it should also be 
considered that in a private health care system, as is the case for the American setting, costs may 
have been more closely monitored for reimbursement purposes. This could also account for some of 
the difference between the cost of VAP presented here and previously published data. Also, in this 
study, the HRG codes were used to calculate the costs whereas in other reports both direct and 
indirect costs were included when the economic implication of VAP was assessed (8). However, 
these costs may still be an under-estimate as the indirect costs to the patients and their caregivers 
were not taken into consideration. 
The incidence of VAP has been estimated to up to 30% in general ICU patients (20).  Furthermore, in 
cardiac surgery the mortality associated with VAP has been reported to be around 40% (24,25). In 
this study, the VAP incidence in a post-op cardiac surgery patient was 10% with a mortality of 4.7%. 
The latter although higher than when VAP did not occur, was still well below what was previously 
thought to be the mortality rate associated with VAP, considering that the current population (post-op 
cardiac surgery patients) was different from the other reports (general ICU patients) (1). Moreover, 
this low mortality may also reflect a very pro-active management of any complication when it does 
arise in our service which is fully consultant-based be it in cardiac surgery, Cardiac anaesthesiology 
or cardiac intensive care. Generally survival after cardiac surgery in the UK is very good. 
According to He et al’s meta-analysis, the most common pathogen causing VAP belongs to the gram-
negative bacteria (GNB) group with Pseudomonas being a leading pathogen. The current study also 
confirms GNB to be the leading cause of VAP but in this series Haemophilus species was the major 
pathogen. This, most likely, reflects the fact that in the current series, the intubation times were much 
shorter. Gram-positive bacteria also caused VAP and could have been introduced during the process 
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of intubation. A recent publication that reviewed BAL samples in 240 patients showed that most VAP 
are due to aspiration of pooled secretions around the endotracheal tube cuff (usually gastric content 
based), translocation of bacteria along the inner lining of the ET tube or direct contamination during 
intubation (11,26). 
Prevention is the best strategy against VAP as treatment of VAP is limited and VAP is associated with 
poor outcomes. Efforts such as; early extubation, strict hand hygiene and enforcement of Institute of 
Healthcare Improvement (IHE) recommended infection prevention ‘ventilator bundles’ help towards 
reducing the risk of VAP. Furthermore some will also advocate chlorhexidene mouthcare (27) and 
selective gut decontamination (28) to reduce the risk of VAP. ET tubes with better cuff management 
systems provide a good seal and thereby prevent micro-aspirations (2,29,30). Early administration of 
antibiotics at clinical suspicion of VAP is appropriate as delay in starting antibiotics is associated with 
poor outcomes. Adopting the above measures in clinical practice may come at a cost. In this study, 
the cost of treating VAP per patient undergoing cardiac surgery was calculated at £8,829. Hence any 
change in managing this issue will be cost-beneficial as long as it is cheaper than £8,829. 
The limitations include those of a retrospective review of prospectively collected data. The CDC VAP 
definition and the HELICS clinical categorisation were used for VAP diagnosis. Although these 
3diagnoses were confirmed as definite VAP, there could have been some bias in categorising 
patients as having VAP. Other VAP definitions were not considered during this study e.g. the CPIS. 
We do recognise this limitation of an appropriate definition but given that the VAP definitions were 
constantly being updated, we have used these two definitions, which were in practice during the 
period of the study. Moreover, although the patients were propensity matched, as in all studies using 
this method, selection bias cannot be completely excluded. Ventilation time was not entered in the 
propensity model as only a minority of patients were ventilated for more than 48 hours (3%) and most 
of these patients were those in the VAP group. This would have excluded a good proportion of VAP 
patients and would not have provided a true reflection of the actual cost of treating patients who 
develop VAP as most of this cost would include the increased ventilation time, increased ICU stay 
and the ensuing complications. Likewise, post-op complications were not used in the propensity 
model, as only patients who developed VAP as their first main complication, were included in the VAP 
group. However, it might have been possible that these patients were already having sub-clinical 
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complications, which had not as yet been the prime problem in their management. Finally this is a 
single centre based study with its inherent limitations.  
From a UK perspective, future studies will need to assess the cost-benefit of proposed interventions 
to reduce VAP and prove that introducing and adopting such interventions represents an efficient use 
of available health care resources. In conclusion VAP after cardiac surgery is associated with 
significant morbidity. Its treatment amounts to significant costs to any type of healthcare system 
whether direct or indirect costs or both are included. Prevention strategies should be evaluated for 
cost-effectiveness and could represent the best option for improving patients’ outcome and 
hospitalisation costs. 
 
Funding statement: This study was funded by a research grant from Venner and Qualitech groups, 
manufacturer and supplier of the PneuX endotracheal tube, respectively. Although the company 
provided the funding for the study they did not have any direct input in the protocol writing, data 
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Table 1: Health Resource Group activity classification 
HRG code code description 
per diem cost 
(£) 
XC01Z Adult Critical Care - 6 Organs Supported 1,886 
XC02Z Adult Critical Care - 5 Organs Supported 1,712 
XC03Z Adult Critical Care - 4 Organs Supported 1,594 
XC04Z Adult Critical Care - 3 Organs Supported 1,449 
XC05Z Adult Critical Care - 2 Organs Supported 1,266 
XC06Z Adult Critical Care - 1 Organs Supported 890 
XC07Z Adult Critical Care - 0 Organs Supported 643 
  One day Cardiothoracic Ward stay 383 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
15 
Table 2: Pre-operative patient characteristics 
  VAP (n=338) No VAP (n=338) 
Age
*
, years 65.9 (10.9) 65.6 (10.8) 
Males (n, %) 269 (80%) 281 (83%) 
Caucasian (n, %) 289 (86%) 284 (84%) 
Diabetics (n, %) 95 (28%) 96 (28%) 
Lung disease (n, %) 83 (25%) 80 (24%) 
Smokers (n, %) 64 (19%) 68 (20%) 
PVD (n, %) 71 (21%) 77 (23%) 
Elective (n, %) 183 (54%) 172 (51%) 
Impaired LV (n, %) 108 (32%) 120 (35%) 
Isolated CABG (n, %) 168 (50%) 176 (52%) 
Isolated valve (n, %) 38 (11%) 40 (12%) 
Log EuroScore
*
 7.85 (8.54) 7.54 (8.29) 
 
 
*
 denotes data expressed as mean (SD) 
PVD: peripheral vascular disease 
LV: left ventricular function 
CABG: coronary artery bypass grafting 
 
 
 
 
 
 
  
16 
Table 3: Intra and post-operative data  
 
 
VAP (n=338) No VAP (n=338) p-Value 
Number of CABG grafts
* 
2.4 (1.7) 2.4 (1.6) 0.7 
Atrial Fibrillation
+
 154 (46%) 86 (25%) <0.001 
Facial CPAP
+
 47 (14%) 6 (2%) <0.001 
Re-intubation
+
 44 (13%) 8 (2%) <0.001 
Tracheostomy
+
 35 (10%) 5 (2%) <0.001 
CVA/TIA
+
 11 (3%) 8 (2%) 0.6 
Confusion
+
 67 (20%) 24 (7%) <0.001 
CVVHF
+
 69 (20%) 17 (5%) <0.001 
Re-admission to CICU
+
 25 (7%) 10 (3%) <0.01 
Survival
+
 322 (95.3%) 327 (96.7%) 0.3 
 
*
 denotes mean (SD) 
+
 denotes data expressed as N (%)  
For the percentages of patients requiring facial CPAP, re-intubation and tracheostomy, patients were 
classed according to the highest level of ventilatory support required.  
CPAP: continuous positive airway pressure 
CVA/ TIA: transient or permanent neurological dysfunction 
CVVHF: continuous veno-venous haemofiltration 
CICU: Cardiac Intensive Care Unit 
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Table 4: Cost of VAP based using the HRG 
Cost category 
VAP no VAP 
Difference (£) BCa 95% CI (£) 
Mean (£) SD (£) Mean (£) SD (£) 
ICU stay 12,117 17,400 4,178 5,953 7,939 6,222 10,071 
Ward stay 3,007 3,322 2,117 1,905 890 521 1,336 
Total 15,124 18,993 6,295 6,787 8,829 6,937 11,189 
 
 
 
 
 
 
 
 
 
 
 
